Restenosis, a process characterized in part by excessive smooth muscle cell (SMC) 
pholates the prdrug gaovir to form a nuclside anal that inhibits DNA synthesis. Culture primary rat SMCs infected with AdMLP.HSTK were completely growth-inhibited by incubation in nclovir-coaing im. In addition, when only a portion of the SMC populaon received the HSV tk t ne, an inhitory effect on neighboring SMCs was evident Evaluation of this strategy in vivo usin a rat carotid balloon ury model demonstratedthatlocalinfectionofinjuredarterieswithAdMLP.-HSTK followed by 2 weeks of systemic gaovir eatment signifcanty (P < 0.01) reduced injury-induced SMC accumulation. In contrast, there was no suppression of injury-induced SMC accumulation in animals infected with AdMLP.HSTK but not receivin gancicovir or in those animals infected with a control adenovirus and either treated or not tated with gancclovir. These results demonstrate the potential utility of adenovirus-m gene transfer for treatment of restenosis after balloon iiuury.
It is estimated that in 1994, >400,000 patients in the United States will undergo percutaneous transluminal coronary balloon angioplasty (PTCA) for treatment of coronary artery disease. Although PTCA is initially successful in >95% of patients, recurrent narrowing of the successfully dilated coronary arteries leads to treatment failures in 30-50%o of patients over the ensuing 3-6 months (1, 2) . In addition, restenosis is largely responsible for the treatment failures of newer techniques, which include atherectomy, stent implantation, and laser angioplasty. Considerable effort has therefore been expended to determine the mechanisms involved in restenosis as well as to devise effective treatment strategies.
We and others have recently shown that adenovirus vectors can efficiently transfer genes into the cells ofboth injured and uninjured vessels (3) (4) (5) (6) (7) . In addition, using a rat carotid injury model, we have shown that smooth muscle cells (SMCs) that form the neointimal layer can be selectively targeted for gene transfer (7) . Using such strategies, the efficiency of adenovirus-mediated gene transfer into vascular cells appears to be significantly greater than previous methods with either liposomes or retroviruses (8, 9) . In an effort to expand treatment options for restenosis, we have investigated the feasibility of targeting neointimal SMCs with genes whose products inhibit cellular proliferation.
Several investigators have previously demonstrated that cellular expression of the herpes simplex virus thymidine kinase (HSV tk) gene product along with concomitant administration of the prodrug ganciclovir produces a potent antiproliferative effect on neoplastic cells (10) (11) (12) (13) . This is thought to result from the ability of the HSV tk gene product to phosphorylate ganciclovir to form a nucleoside analog that in turn inhibits DNA replication (14) . Moreover, because the nucleoside analog is diffusible, neighboring nontransfected cells may also be affected through a "bystander effect," thereby amplifying the antiproliferative actions (15, 16) . Recent reports of experiments using such strategies have demonstrated that intratumor injection of fibroblasts engineered to produce HSV tk retroviral vectors, along with ganciclovir treatment, results in tumor regression in animals (15) . This strategy is being evaluated in human subjects with brain tumors (17) . In the present study, we show that we can use adenovirus vectors to deliver HSV tk into neointimal SMCs and, in the presence of ganciclovir, inhibit the development of injury-induced SMC accumulation. (Fig. 2) . Primary cultures of rat SMCs were infected with AdMLP.HSTK and incubated in medium containing various concentrations of ganciclovir. As shown in Fig. 2A, ganciclovir at 10 ug/ml completely inhibited SMC growth, while at 1 j.g/ml the reduction in cell number was =70%o at the end of the 2-week period. This same range of ganciclovir only modestly affected cell growth when SMCs were infected with the control adenovirus AdRSV./3gal (Fig. 2B) . The antiproliferative effect of AdMLP.HSTK was also dependent on the moi in that growth inhibition of SMCs increased as the moi increased from 0 to 100 pfu per cell (Fig. 2C) .
MATERIALS AND METHODS
Previous experiments with transformed cells demonstrated a bystander effect wherein tumor cells expressing HSV tk exert an antiproliferative effect on neighboring cells that do not express HSV tk. To assess whether primary rat SMCs were also susceptible to the bystander effect, cells were infected with either AdMLP.HSTK or AdRSV.(GAL and then mixed and replated (day 0) in various proportions. Since we had previously shown in vivo that between 10%o and 75% of neointimal cells were successfully transduced by adenoviral infection (7), similar ratios of HSV tk-infected and noninfected cells were prepared in vitro. The following day (day 1), ganciclovir (10 pg/ml) was added to the medium. At the end of 7 days, the -fold increase in cell number from day 1 was determined. As shown in Fig. 3 These in vitro data indicate that adenovirus-mediated gene transfer of HSV tk can inhibit SMC proliferation and that this effect can be maintained for at least 2 weeks in vitro even though the adenovirus genome does not integrate into the host cell genome (24) and even in the absence of 100%1 HSV tk gene transfer. This time frame is important because experimental evidence indicates that most neointimal proliferation in the rat lesion occurs within the first few weeks after injury (21) .
In area was determined by digital planimetry as described (22) . The mean neointimal/medial ratios in the four control groups were statistically indistinguishable (Fig. 5) . In contrast, administration of AdMLP.HSTK with a fixed dose of ganciclovir significantly reduced the mean neointimal/medial ratio (P = 0.027). The observed reduction in neointimal/medial ratio was entirely dependent on reduction of the neointimal area, as the medial area did not differ significantly among the six groups (P = 0.38; data not shown). Visual examination of histological sections from animals in the four control groups all showed appreciable neointimal formation when compared to uninjured arteries (Fig. 4 A-D) . In contrast, the neointimal mass appeared qualitatively reduced in those animals infected with AdMLP.HSTK and treated with ganciclovir ( Fig. 4 E and F) .
To quantify the apparent reduction in neointimal area seen in the two treatment groups, the ratio of neointimal/medial The magnitude of neointimal reduction in the treated groups was dependent on the amount of AdMLP.HSTK used (Fig. 5) . Compared to the four control groups, animals infected with the lower dose of 3 x 108 pfu of AdMLP.HSTK and treated with systemic ganciclovir had an~200% reduction of the neointimal/medial ratio, a reduction that approached statistical significance (P = 0.058). At the higher dose of 1 x 109 pfu of AdMLP.HSTK, the reduction of neointimal/ medial ratio was 46% (P < 0.01). Linear regression analysis of percentage neointimal reduction versus adenovirus dose was performed with three groups (vehicle, low dose, and high dose AdMLP.HSTK). This analysis revealed a slope that was significantly different from 0 (P = 0.004), indicative of a dose-response relationship. A similar linear or near-linear relationship between in vivo adenovirus dose and gene expression has previously been observed in marker gene studies in the heart, vasculature, and lung (4, 25, 26) .
Analysis of carotid arteries 7 days after balloon injury, the time corresponding to adenoviral infection, revealed a neointimal/medial ratio of 0.27 ± 0.19 (n = 6). The neointimal/medial ratio at 21 days in the two AdMLP.HSTKinfected groups treated with ganciclovir was larger (P < 0.05), suggesting that treated lesions did not regress in size but rather that neointimal progression in the treated groups was inhibited. These results are similar to those obtained in the in vitro mixing experiments (Fig. 3) wherein some growth occurs when only 25-75% of cells contain the HSV tk gene. Whether the differences in the neointimal/medial ratio persist beyond 3 weeks is currently unknown.
Finally, since intravascular delivery of adenovirus has potential for widespread infection beyond the treated area, we assessed the presence of viral DNA in distal organs. DNA was extracted from the liver, spleen, myocardium, gonadal tissue, and infected carotid segment 48 hr after infection and used in the PCR. No adenoviral DNA was detected in any organ other than the infected carotid segment. This suggests that the methodology for local delivery of adenovirus that was used resulted in little distal infection.
DISCUSSION
Although various pharmacological interventions have been used in an effort to inhibit the proliferation ofSMCs at the site of angioplasty, none has significantly affected the rate of restenosis in humans (27) . Newer strategies have recently been evaluated, including antibodies directed against peptide growth factors (28, 29) , and oligonucleotide-antisense molecules directed at transcription factors or cell-cycle regulatory molecules required for proliferation (30, 31) . This study expands potential treatment options for restenosis by demonstrating that adenovirus-mediated transfer of a therapeutic gene into the vascular wall inhibits neointimal development.
Before these technologies can be contemplated for use in patients, other animal models need to be assessed to overcome the differences that exist between the rat model and more complex human lesions. While the rat lesion is composed of proliferating SMCs the kinetics of which are well described, the human lesion contains other cell types and includes contributing factors such as vessel remodeling, thrombus formation, and matrix secretion. Therefore, a strategy such as we described targeted solely at SMC proliferation may prove less effective in humans than in rats. However, it is currently thought that, in human lesions, neointimal SMCs produce much of the lesion's extracellular matrix and serve as a major source of chemoattractant factors. In such an event, it remains conceivable that the elimination of neointimal SMCs may have significant effects even in the more complex human lesion.
Perhaps because the rat model is primarily a model of SMC proliferation, and even though we have previously noted an inflammatory response to adenoviral infection in the myocardium (32), we noted little inflammation by light microscopy in infected vessels (Fig. 4) Another question that needs to be addressed in the future is whether efficacy can be further enhanced. Since we demonstrated a dose-response relation between the amount of virus used and the degree of inhibition of neointimal development, it is possible that increasing the expression of HSV tk either by higher titers or by using a stronger promoter might increase efficacy. In addition, since the present insert capability of recombinant adenovirus is up to 7.5 kb (24), it is also possible that adenovirus vectors encoding HSV tk (or another gene whose product has potent antiproliferative effects) in combination with other therapeutic genes could be constructed. As such, a recombinant vector that encodes multiple gene products, some with antiproliferative effects and others with antithrombotic or antiplatelet effects, might ultimately prove to be the most clinically useful. Finally, because virus leakage will probably occur when delivered by a catheter-based system, use of a SMC-specific promoter may be desirable to achieve optimal safety.
It should be noted that previous applications with recombinant adenovirus vectors have primarily involved inherited genetic diseases such as cystic fibrosis, muscular dystrophy, or hemophilia (34) (35) (36) (37) . Such conditions require continuous stable gene expression, which presently cannot be achieved with nonintegating adenoviral vectors. In contrast, the application of adenoviral gene transfer may be better suited to conditions such as restenosis, which presumably require short-term gene expression. As such, the present investigation should provide an impetus to further evaluate such strategies in the treatment of acquired cardiovascular disorders.
